Overweight and Obese AdultsNCT07583875
Dose Response of Leucine on Muscle Maintenance During Weight Loss
A study testing leucine in people with Overweight and Obese Adults and BMI >= 23, run by Nanyang Technological University at 1 site in Singapore.
Trial summary
The objective of this research is to determine if there is dose response of leucine on muscle maintenance during 4-week of alternate-day fasting (ADF) on blood parameters, body composition, mood and parameters related to appetite in young men with a body mass index of 23kg/m2 and above, whose body mass falls outside… Read more about this study
- Who is it for?
- Ages 21 to 35 years, men only
- Conditions the study is for
- Overweight and Obese Adults, BMI >= 23
- What is being tested?
- leucine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 92 participants
- Where
- 1 siteSingapore
- Study dates
- 18 Aug 2020to 11 Feb 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 35 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Male
- 21 to 35 years old
- Do not smoke or use tobacco products (including shisha)
- Have a body mass index (BMI = body mass in kilograms divided by the square of height in metres) of 23 or greater
Who cannot join
- Unable to adhere to the requirements regarding physical activity and diet as stated in the research methodologies.
- Allergic or intolerant to milk and soy.
- Any other food allergies or dietary restrictions/preferences that the research team is unable to cater to due to constraints in food preparation and choices in order to control for composition of macronutrients, leucine content and calories in the food provided.
- Failed an exercise stress test.
- Have any health condition(s) that would be made worse by fasting.
- Taking long-term prescribed medication(s) for heart, blood (including blood sugar and blood pressure), lung (except controlled asthma), liver, kidney or joint condition(s).
- Taking other prescribed medication (including traditional Chinese medicine and other alternative medicine), drugs, steroids, or hormones that can affect any of the measurements in this study.
- Have electrical implant (such as pacemaker, implantable cardioverter defibrillator or neurostimulator), metal or plastic implant/rod/plate, or joint replacement in the body as these objects can affect the accuracy of the body composition measurement.
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this research is to determine if there is dose response of leucine on muscle maintenance during 4-week of alternate-day fasting (ADF) on blood parameters, body composition, mood and parameters related to appetite in young men with a body mass index of 23kg/m2 and above, whose body mass falls outside of the healthy range for their height (Asian reference point for increased risk of cardiovascular diseases). Participants have no diagnoses of, and are not prescribed medications for, cardiovascular, metabolic, diabetic, lung (except controlled asthma), kidney, or joint health conditions.
To achieve this objective, 100 hundred young men, aged between 21 and 35 years old will be recruited to complete a 4-week ADF programme. The fasting programme starts at 12 midnight and alternates between fasting and feeding days. Each fasting or feeding day is 24 hours in duration. During fasting days, participants abstain from all food and beverages except for ad libitum plain water and other zero-calorie beverages, and a small meal amounting to 25% of daily caloric need. This small meal must be consumed between 12 pm and 2 pm in this study, for standardization to ensure consistency in the total duration of fasting and feeding. During feeding days, participants eat up to approximately 125% of daily caloric need (calculated weekly), with no restriction on meal timing as long as meals are consumed within the 24-hour period. The programme ends after 4 weeks (28 days) of continuous ADF
Read more
All food for the 4-week ADF will be provided. Participants will be randomly assigned (double blind) to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days.
Blood parameters, body mass, height, waist-to-hip ratio, body composition, mood, stress level, and parameters related to eating and appetite will be measured before and after 4-week of ADF.
The investigators hypothesised a dose response in leucine to maintain muscle mass during weight loss.
Read the detailed description
Participation in this study requires a total of 4 weeks of ADF and 6 laboratory visits (sessions) spread over 5-6 weeks.
To participate in this study, participants will have to:
- complete the questionnaires regarding their health and diet and physical activity level (Global Physical Activity Questionnaire) on session 1,
- complete 5 weekly measurements of resting blood pressure and heart rate, fasting blood glucose (via finger prick blood sample), body mass, height, waist and hip circumferences, and body composition using bioelectrical impedance analysis (BIA) on sessions 1 and 3-6,
- complete the questionnaires regarding their mood [Brunel Mood Scale (BRUMS)], stress [Perceived Stress Scale (PSS)], food craving for general and specific foods [Food Craving Questionnaire-Trait Reduced (FCQ-T-r), and Food Craving Inventory (FCI)], eating behaviour [Three-Factor Eating Questionnaire-R18 - cognitive restraint component (TFEQ-r18)], and appetite, hunger, satiety and diet satisfaction (visual analogue scales, questionnaire and computerised test) twice on sessions 1 and 6,
- provide blood samples twice on sessions 1 and 6 for various biomarkers,
- complete 2 occasions of body composition measurement using dual-energy X-ray absorptiometry (DXA) on sessions 1 and 6,
- complete 4 weeks of ADF as instructed (details given below),
- consume only the food provided (high protein diet with leucine supplement) except for ad libitum intake of plain water and zero caloric beverages during the 4 weeks of ADF,
- complete daily log of food intake (including leftover/unconsumed food), physical activity and sleep during the entire 4 weeks of ADF,
- maintain a consistent diet between session 1 and the start of ADF,
- maintain a consistent physical activity level throughout the entire study. Do not start a new exercise programme during the entire duration of the study, and
- abstain from high level of physical activity throughout the entire study.
Prior to each session except session 2, participants are also required to:
- Abstain from any physical activity except activities of daily living for at least 48 hours.
- Abstain from alcohol and caffeine for at least 24 hours.
- Fast (i.e. do not eat or drink except plain water) overnight for 10 hours. In consideration of the fasting, these sessions will take place in the morning. To control for diurnal variation, the sessions will be timed such that the same measurements will be taken at approximately the same time of the day (+/- 1 hour difference).
- Obtain a full night of sleep the night before.
The above dietary and physical activity restriction is to minimise the confounding effects of diet and physical activities external to those conducted in this study.
Participants will also be instructed to:
- Inform the investigators immediately if they fall ill during the study or discover a health condition that requires them to consume any medication, steroids or hormones, and
- NOT to take calcium supplements or antacids (e.g. TUMS®) at least 24 hours prior to session 1, and NOT to schedule any scan that involves a contrast agent or ingestion of barium at least 14 days prior to sessions 1 and 6 to ensure accuracy of the DXA scans for body composition.
All sessions will be done in a fasted and rested state except session 2.
Session 1:
- Read and sign consent form
- Pre-screening:
- Complete questionnaire on health and diet
- Resting blood pressure and heart rate
- Fasting blood glucose (via finger prick)
- Body mass
- Height
- Complete questionnaires on physical activity level, mood, stress, food craving, eating behaviour, appetite, hunger, satiety and diet satisfaction
- Antecubital blood sample
- Waist and hip circumference measurements
- Body composition using dual-energy X-ray absorptiometry and bioelectrical impedance analysis
Session 2: collection of 1 week of food. ADF will start within 10 days from session 1. Body mass and height
Session 3: 7 days (1 week) after the start of ADF
- Health measurements as in session 1:
- Resting blood pressure and heart rate
- Fasting blood glucose (via finger prick)
- Body mass and height
- Waist and hip circumferences
- Body composition using bioelectrical impedance analysis
- Collection of 1 week of food
Session 4: 14 days (2 weeks) after start of fasting programme
- Same as session 3
Session 5: 21 days (3 weeks) after start of fasting programme
- Same as session 3
Session 6: 28 days (4 weeks) after start of fasting programme
- Same as session 1 except consent and pre-screening questionnaires on health and diet, and physical activity level are not applicable
- Conditions
- Overweight and Obese Adults, BMI >= 23
- Being tested
- leucine
- Keywords
- Overweight, Obesity, Intermittent fasting, Alternate Day Fasting, ADF, Protein, Leucine, Skeletal muscle, quality weight loss, dose response, muscle maintenance, blood health markers, mood, appetite, food craving
- Medical subject headings
- Overweight, Obesity, Intermittent Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
leucineDietary supplement
0.02g/kg body mass/meal
leucineDietary supplement
0.04g/kg body mass/meal
leucineDietary supplement
0.06g/kg body mass/meal
leucineDietary supplement
0.08g/kg body mass/meal
| Study group | Role | What they receive |
|---|---|---|
| 0.02g/kg body mass per meal | Experimental | In this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. Receives: Dietary Supplement: leucine |
| 0.04g/kg body mass per meal | Experimental | In this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. Receives: Dietary Supplement: leucine |
| 0.06g/kg body mass per meal | Experimental | In this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. Receives: Dietary Supplement: leucine |
| 0.08g/kg body mass per meal | Experimental | In this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. Receives: Dietary Supplement: leucine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body mass
Body mass
Measured: Start and end of 4-week intervention and weekly during intervention
Lean mass
Lean mass measured using DXA
Measured: Start and end of 4-week intervention
Appendicular Lean Mass
Sum of lean mass in upper and lower limbs measured using DXA
Measured: Start and end of 4-week intervention
Body mass index
body mass in kilograms divided by sqaure of height in metres
Measured: Start and end of 4-week intervention and weekly during intervention
Lean mass index
lean mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention
Appendicular lean mass index
Appendicular lean mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention
Fat mass
Fat mass
Measured: Start and end of 4-week intervention and weekly during intervention
Percentage body fat
Percentage body fat
Measured: Start and end of 4-week intervention and weekly during intervention
Fat mass index
Fat mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention and weekly during intervention
Trunk fat
Fat mass around the trunk
Measured: Start and end of 4-week intervention
Appendicular fat mass
Sum of fat mass in the upper and lower limbs
Measured: Start and end of 4-week intervention
Appendicular fat mass index
Appendicular fat mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention
Resting systolic blood pressure
Measured: Start and end of 4-week intervention and weekly during intervention
Resting diastolic blood pressure
Measured: Start and end of 4-week intervention and weekly during intervention
Fasting blood glucose
Measured: Start and end of 4-week intervention and weekly during intervention
HbA1c
Measured: Start and end of 4-week intervention
Insulin
Measured: Start and end of 4-week intervention
The HOMA-IR index
Homeostatic Model Assessment of Insulin Resistance index
Measured: Start and end of 4-week intervention
Total cholesterol
Measured: Start and end of 4-week intervention
HDL cholesterol
Measured: Start and end of 4-week intervention
LDL cholesterol
Measured: Start and end of 4-week intervention
Total cholesterol to HDL cholesterol ratio
Measured: Start and end of 4-week intervention
Triglycerides
Measured: Start and end of 4-week intervention
Secondary outcomes (28)
Android fat mass
Measured: Start and end of 4-week intervention
Gynoid fat mass
Measured: Start and end of 4-week intervention
Bone mineral content
Bone mass
Measured: Start and end of 4-week intervention
Bone mineral density
Bone mineral density
Measured: Start and end of 4-week intervention
Waist Circumference
Waist Circumference
Measured: Start and end of 4-week intervention and weekly during intervention
Hip circumference
Measured: Start and end of 4-week intervention and weekly during intervention
Waist-to-hip ratio
Waist circumference to hip circumference ratio
Measured: Start and end of 4-week intervention and weekly during intervention
Fat free mass
Fat free mass measured using BIA
Measured: Start and end of 4-week intervention and weekly during intervention
Skeletal muscle mass
Skeletal muscle mass measured using BIA
Measured: Start and end of 4-week intervention and weekly during intervention
Appendicular fat-free mass
Sum of fat free mass in upper and lower limbs measured using BIA
Measured: Start and end of 4-week intervention and weekly during intervention
Visceral fat area
Visceral fat area measured using BIA
Measured: Start and end of 4-week intervention and weekly during intervention
Fat-free mass index
Fat-free mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention and weekly during intervention
Skeletal muscle mass index
Skeletal muscle mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention and weekly during intervention
Appendicular fat-free mass index
Appendicular fat-free mass in kilograms divided by square of height in metres
Measured: Start and end of 4-week intervention and weekly during intervention
Insulin growth factor-1
Measured: Time Frame: Start and end of 4-week intervention
Mood
Brunel Mood Scale (BRUMS). BRUMS is the modified and shorter version of the Profile of Mood Stats (POMS). The 24-item BRUMS was used to assess mood responses. It has six subscales (tension, depression, anger, vigour, fatigue, and confusion) of four mood descriptors each, with respondents rating how they feel "right now" on a 5-point Likert-type scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit; 4 = extremely). During its development, the BRUMS showed robust psychometric properties across samples of adult students, adult athletes, young athletes, and schoolchildren, and has since demonstrated psychometric integrity for use with many other population groups (doi.org/10.3390/su13116116).For each subscale, the raw score are summed and converted to a T-score based on the norms published in the paper (doi.org/10.3390/su13116116). Higher T-score for each subscale reflects higher profile of that subscale (i.e. tension, depression, anger, vigour, fatigue, or confusion).
Measured: Start and end of 4-week intervention
Stress level
Perceived Stress Scale (PSS). The 10-item PSS asks participants about feelings and thoughts during the last month, with responses ranging from 0 (never) to 4 (very often). The final score obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. Higher scores indicating higher levels of perceived stress.
Measured: Start and end of 4-week intervention
Food craving - habitual
The Food Craving Questionnaire-Trait Reduced (FCQ-T-r) measures the habitual (unspecified time frame) trait craving for food in general. It predicts food cravings in daily life. It represents a stable trait but is also sensitive to changes in eating behaviour. The questionnaire consists of 15 questions, participants are required to rate the frequency of each statement with a 6-likert scale (never or not applicable = 1, to always = 6). By summing up the scores of the scales, higher scores represent higher level of food cravings.
Measured: Start and end of 4-week intervention
Food craving - specific foods
Food Craving Inventory (FCI) measures food craving for specific foods and the versions validated for use in United States and United Kingdom were used. Questionnaire items pertaining to specific local foods were also added for a combined total of 61 food items (i.e. questionnaire items). For each item, participants were asked how often they have experienced a craving for that particular food on a 5-point Likert scale (never = 1, to always/almost every day = 5). The higher the score, the higher the food craving.
Measured: Start and end of 4-week intervention
Eating Behaviour
Three-Factor Eating Questionnaire-R18 - cognitive restraint component (TFEQ-r18 Cog). It has 6 items and each scored 1 to 4 for a total of 24 points. The higher the total score, the more disordered the eating behaviour.
Measured: Start and end of 4-week intervention
Hunger over past 4 weeks
Hunger over past 4 weeks. Visual analogue scale 0 to 100. The higher the number the greater the amount of hunger.
Measured: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Baseline appetite
Baseline appetite using visual analogue scale 0 to 100. The higher the score, the higher the baseline appetite
Measured: Start and end of 4-week intervention upon arrival in the laboratory
Satiety over past 4 weeks
Satiety over past 4 weeks. Visual analogue scale 0 to 100. The higher the number, the greater amount of satiety.
Measured: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Diet satisfaction over past 4 weeks
Diet satisfaction over past 4 weeks. Visual analogue scale 0 to 100. The higher the number the greater the satisfaction.
Measured: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Implicit satiety goal
Implicit satiety goal (unconscious, habitual, or subjective levels of fullness that individuals aim to achieve when eating) using visual analogue scale 0 to 100. The higher the number, the greater implicit satiety goal.
Measured: Start and end of 4-week intervention
Ideal portion size
Ideal portion size (IPS). Participants were presented with a diverse range of 25 foods typically consumed in Singapore. The computerised portion selection tasks presented a series of 50 images of each food that increased in portion size in 20 kcal increments (20-1000 kcal). Participants could increase or decrease the portion size by 20 kcal using the left and right arrow-keys on the keyboard and were encouraged to view the full range of portions before selecting their ideal portion. Foods were presented in a randomised order and an average portion size for each participant was calculated by averaging the selected portion sizes of all 25 foods (α = 0.95). This created an overall index of IPS.
Measured: Start and end of 4-week intervention
Expected satiety
Expected satiety (ES) measured using computerised task. The ES task followed the same format as the IPS task, in other words, 50 images were presented depicting 20 kcal increment changes in portion size. This task sought to measure participants' expectations about how satiating a diverse range of foods were. Larger portions selected indicated that participants require larger quantities of the food to delay the onset of hunger, in other words they have lower expected satiety. The same 25 foods presented in the IPS were also presented in the ES in a randomised order and were averaged to create an overall index of ES (α = 0.95).
Measured: Start and end of 4-week intervention
Food-related characteristics
A single image of each food item was presented to participants alongside questions of food-related characteristics. Participants were asked to rate how filling they expected each food to be (not filling at all (0) to very filling (100)), how much they like each food in general (not at all (0) to very much (100)) and how often they eat each food (never (0) to more than once a week (5)). Each food was presented in a randomised order and average scores across all 25 foods for participants perceptions of how filling, frequently consumed and preference for foods were calculated.
Measured: Start and end of 4-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2026
- Study start18 Aug 2020
- Primary completion11 Feb 2021
- Study completion11 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight and Obese AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This was a four-arm randomized controlled trial with a double-blind design
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nanyang Technological University
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Education, Singapore
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07583875
- Sponsor's protocol ID
- IRB 2019-07-039
- Status last verified
- Apr 2026
- First submitted
- 26 Apr 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD sharing will be available upon request.
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose Response of Leucine on Muscle Maintenance During Weight Loss
- ClinicalTrials.gov ID
- NCT07583875
- Acronym / sponsor ID
- IRB 2019-07-039
- Conditions
- Overweight and Obese Adults, BMI >= 23
- Keywords
- Overweight, Obesity, Intermittent fasting, Alternate Day Fasting, ADF, Protein, Leucine, Skeletal muscle
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- Nanyang Technological UniversityUniversity, hospital or other
- Collaborators
- Ministry of Education, Singapore
- Study start
- 18 Aug 2020 (actual)
- Primary completion
- 11 Feb 2021 (actual)
- Study completion
- 11 Feb 2021 (actual)
- First posted
- 13 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this research is to determine if there is dose response of leucine on muscle maintenance during 4-week of alternate-day fasting (ADF) on blood parameters, body composition, mood and parameters related to appetite in young men with a body mass index of 23kg/m2 and above, whose body mass falls outside of the healthy range for their height (Asian reference point for increased risk of cardiovascular diseases). Participants have no diagnoses of, and are not prescribed medications for, cardiovascular, metabolic, diabetic, lung (except controlled asthma), kidney, or joint health conditions.
To achieve this objective, 100 hundred young men, aged between 21 and 35 years old will be recruited to complete a 4-week ADF programme. The fasting programme starts at 12 midnight and alternates between fasting and feeding days. Each fasting or feeding day is 24 hours in duration. During fasting days, participants abstain from all food and beverages except for ad libitum plain water and other zero-calorie beverages, and a small meal amounting to 25% of daily caloric need. This small meal must be consumed between 12 pm and 2 pm in this study, for standardization to ensure consistency in the total duration of fasting and feeding. During feeding days, participants eat up to approximately 125% of daily caloric need (calculated weekly), with no restriction on meal timing as long as meals are consumed within the 24-hour period. The programme ends after 4 weeks (28 days) of continuous ADF
All food for the 4-week ADF will be provided. Participants will be randomly assigned (double blind) to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days.
Blood parameters, body mass, height, waist-to-hip ratio, body composition, mood, stress level, and parameters related to eating and appetite will be measured before and after 4-week of ADF.
The investigators hypothesised a dose response in leucine to maintain muscle mass during weight loss.
Detailed description
Participation in this study requires a total of 4 weeks of ADF and 6 laboratory visits (sessions) spread over 5-6 weeks.
To participate in this study, participants will have to:
- complete the questionnaires regarding their health and diet and physical activity level (Global Physical Activity Questionnaire) on session 1,
- complete 5 weekly measurements of resting blood pressure and heart rate, fasting blood glucose (via finger prick blood sample), body mass, height, waist and hip circumferences, and body composition using bioelectrical impedance analysis (BIA) on sessions 1 and 3-6,
- complete the questionnaires regarding their mood [Brunel Mood Scale (BRUMS)], stress [Perceived Stress Scale (PSS)], food craving for general and specific foods [Food Craving Questionnaire-Trait Reduced (FCQ-T-r), and Food Craving Inventory (FCI)], eating behaviour [Three-Factor Eating Questionnaire-R18 - cognitive restraint component (TFEQ-r18)], and appetite, hunger, satiety and diet satisfaction (visual analogue scales, questionnaire and computerised test) twice on sessions 1 and 6,
- provide blood samples twice on sessions 1 and 6 for various biomarkers,
- complete 2 occasions of body composition measurement using dual-energy X-ray absorptiometry (DXA) on sessions 1 and 6,
- complete 4 weeks of ADF as instructed (details given below),
- consume only the food provided (high protein diet with leucine supplement) except for ad libitum intake of plain water and zero caloric beverages during the 4 weeks of ADF,
- complete daily log of food intake (including leftover/unconsumed food), physical activity and sleep during the entire 4 weeks of ADF,
- maintain a consistent diet between session 1 and the start of ADF,
- maintain a consistent physical activity level throughout the entire study. Do not start a new exercise programme during the entire duration of the study, and
- abstain from high level of physical activity throughout the entire study.
Prior to each session except session 2, participants are also required to:
- Abstain from any physical activity except activities of daily living for at least 48 hours.
- Abstain from alcohol and caffeine for at least 24 hours.
- Fast (i.e. do not eat or drink except plain water) overnight for 10 hours. In consideration of the fasting, these sessions will take place in the morning. To control for diurnal variation, the sessions will be timed such that the same measurements will be taken at approximately the same time of the day (+/- 1 hour difference).
- Obtain a full night of sleep the night before.
The above dietary and physical activity restriction is to minimise the confounding effects of diet and physical activities external to those conducted in this study.
Participants will also be instructed to:
- Inform the investigators immediately if they fall ill during the study or discover a health condition that requires them to consume any medication, steroids or hormones, and
- NOT to take calcium supplements or antacids (e.g. TUMS®) at least 24 hours prior to session 1, and NOT to schedule any scan that involves a contrast agent or ingestion of barium at least 14 days prior to sessions 1 and 6 to ensure accuracy of the DXA scans for body composition.
All sessions will be done in a fasted and rested state except session 2.
Session 1:
- Read and sign consent form
- Pre-screening:
- Complete questionnaire on health and diet
- Resting blood pressure and heart rate
- Fasting blood glucose (via finger prick)
- Body mass
- Height
- Complete questionnaires on physical activity level, mood, stress, food craving, eating behaviour, appetite, hunger, satiety and diet satisfaction
- Antecubital blood sample
- Waist and hip circumference measurements
- Body composition using dual-energy X-ray absorptiometry and bioelectrical impedance analysis
Session 2: collection of 1 week of food. ADF will start within 10 days from session 1. Body mass and height
Session 3: 7 days (1 week) after the start of ADF
- Health measurements as in session 1:
- Resting blood pressure and heart rate
- Fasting blood glucose (via finger prick)
- Body mass and height
- Waist and hip circumferences
- Body composition using bioelectrical impedance analysis
- Collection of 1 week of food
Session 4: 14 days (2 weeks) after start of fasting programme
- Same as session 3
Session 5: 21 days (3 weeks) after start of fasting programme
- Same as session 3
Session 6: 28 days (4 weeks) after start of fasting programme
- Same as session 1 except consent and pre-screening questionnaires on health and diet, and physical activity level are not applicable
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- This was a four-arm randomized controlled trial with a double-blind design
| Arm | Type | Receives |
|---|---|---|
| 0.02g/kg body mass per meal | Experimental | Dietary Supplement: leucineIn this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. |
| 0.04g/kg body mass per meal | Experimental | Dietary Supplement: leucineIn this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. |
| 0.06g/kg body mass per meal | Experimental | Dietary Supplement: leucineIn this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. |
| 0.08g/kg body mass per meal | Experimental | Dietary Supplement: leucineIn this study, participants would be randomly (by chance) assigned to the amount of leucine in their diet: 0.02, 0.04, 0.06 or 0.08 g/kg body mass per meal for 1 meal/day on fasting days and 3 meals/day on feeding days. |
Who may qualify
- Ages
- 21 to 35 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Male
- 21 to 35 years old
- Do not smoke or use tobacco products (including shisha)
- Have a body mass index (BMI = body mass in kilograms divided by the square of height in metres) of 23 or greater
Key exclusion criteria (8 listed)
- Unable to adhere to the requirements regarding physical activity and diet as stated in the research methodologies.
- Allergic or intolerant to milk and soy.
- Any other food allergies or dietary restrictions/preferences that the research team is unable to cater to due to constraints in food preparation and choices in order to control for composition of macronutrients, leucine content and calories in the food provided.
- Failed an exercise stress test.
- Have any health condition(s) that would be made worse by fasting.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| leucine0.02g/kg body mass/meal | Dietary supplement | 0.02g/kg body mass per meal |
| leucine0.04g/kg body mass/meal | Dietary supplement | 0.04g/kg body mass per meal |
| leucine0.06g/kg body mass/meal | Dietary supplement | 0.06g/kg body mass per meal |
| leucine0.08g/kg body mass/meal | Dietary supplement | 0.08g/kg body mass per meal |
Primary outcome
Body mass
Time frame: Start and end of 4-week intervention and weekly during intervention
Body mass
Lean mass
Time frame: Start and end of 4-week intervention
Lean mass measured using DXA
Appendicular Lean Mass
Time frame: Start and end of 4-week intervention
Sum of lean mass in upper and lower limbs measured using DXA
Body mass index
Time frame: Start and end of 4-week intervention and weekly during intervention
body mass in kilograms divided by sqaure of height in metres
Lean mass index
Time frame: Start and end of 4-week intervention
lean mass in kilograms divided by square of height in metres
Appendicular lean mass index
Time frame: Start and end of 4-week intervention
Appendicular lean mass in kilograms divided by square of height in metres
Fat mass
Time frame: Start and end of 4-week intervention and weekly during intervention
Fat mass
Percentage body fat
Time frame: Start and end of 4-week intervention and weekly during intervention
Percentage body fat
Fat mass index
Time frame: Start and end of 4-week intervention and weekly during intervention
Fat mass in kilograms divided by square of height in metres
Trunk fat
Time frame: Start and end of 4-week intervention
Fat mass around the trunk
Appendicular fat mass
Time frame: Start and end of 4-week intervention
Sum of fat mass in the upper and lower limbs
Appendicular fat mass index
Time frame: Start and end of 4-week intervention
Appendicular fat mass in kilograms divided by square of height in metres
Resting systolic blood pressure
Time frame: Start and end of 4-week intervention and weekly during intervention
Resting diastolic blood pressure
Time frame: Start and end of 4-week intervention and weekly during intervention
Fasting blood glucose
Time frame: Start and end of 4-week intervention and weekly during intervention
HbA1c
Time frame: Start and end of 4-week intervention
Insulin
Time frame: Start and end of 4-week intervention
The HOMA-IR index
Time frame: Start and end of 4-week intervention
Homeostatic Model Assessment of Insulin Resistance index
Total cholesterol
Time frame: Start and end of 4-week intervention
HDL cholesterol
Time frame: Start and end of 4-week intervention
LDL cholesterol
Time frame: Start and end of 4-week intervention
Total cholesterol to HDL cholesterol ratio
Time frame: Start and end of 4-week intervention
Triglycerides
Time frame: Start and end of 4-week intervention
28 secondary outcomes
Android fat mass
Time frame: Start and end of 4-week intervention
Gynoid fat mass
Time frame: Start and end of 4-week intervention
Bone mineral content
Time frame: Start and end of 4-week intervention
Bone mineral density
Time frame: Start and end of 4-week intervention
Waist Circumference
Time frame: Start and end of 4-week intervention and weekly during intervention
Hip circumference
Time frame: Start and end of 4-week intervention and weekly during intervention
Waist-to-hip ratio
Time frame: Start and end of 4-week intervention and weekly during intervention
Fat free mass
Time frame: Start and end of 4-week intervention and weekly during intervention
Skeletal muscle mass
Time frame: Start and end of 4-week intervention and weekly during intervention
Appendicular fat-free mass
Time frame: Start and end of 4-week intervention and weekly during intervention
Visceral fat area
Time frame: Start and end of 4-week intervention and weekly during intervention
Fat-free mass index
Time frame: Start and end of 4-week intervention and weekly during intervention
Skeletal muscle mass index
Time frame: Start and end of 4-week intervention and weekly during intervention
Appendicular fat-free mass index
Time frame: Start and end of 4-week intervention and weekly during intervention
Insulin growth factor-1
Time frame: Time Frame: Start and end of 4-week intervention
Mood
Time frame: Start and end of 4-week intervention
Stress level
Time frame: Start and end of 4-week intervention
Food craving - habitual
Time frame: Start and end of 4-week intervention
Food craving - specific foods
Time frame: Start and end of 4-week intervention
Eating Behaviour
Time frame: Start and end of 4-week intervention
Hunger over past 4 weeks
Time frame: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Baseline appetite
Time frame: Start and end of 4-week intervention upon arrival in the laboratory
Satiety over past 4 weeks
Time frame: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Diet satisfaction over past 4 weeks
Time frame: Start (i.e. over the past 4 weeks before start of the intervention) and end of 4-week intervention (i.e. over the past 4 weeks during the intervention)
Implicit satiety goal
Time frame: Start and end of 4-week intervention
Ideal portion size
Time frame: Start and end of 4-week intervention
Expected satiety
Time frame: Start and end of 4-week intervention
Food-related characteristics
Time frame: Start and end of 4-week intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: Yes. IPD sharing will be available upon request.
Related trials for Overweight and Obese Adults
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
RecruitingPhase 3
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
Obesity
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing leucine in people with Overweight and Obese Adults and BMI >= 23, run by Nanyang Technological University at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body mass (time frame: Start and end of 4-week intervention and weekly during intervention). The study lists 23 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.